Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

AMETEK entered the second half of 2026 with strong operating momentum: second-quarter sales rose 15%, adjusted EPS rose 17%, adjusted operating margin reached 26.6%, and orders increased 28%. Management consequently raised full-year EPS guidance to $8.20-$8.30. The completed $5.0 billion Indicor Instrumentation acquisition adds differentiated, recurring-revenue-oriented businesses and is expected to contribute approximately $350 million of 2026 sales with modest adjusted-EPS accretion. These merits are balanced by substantial debt-funded acquisition exposure, integration risk.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets18 analysts · as of 18 Aug 2026
Low · most bearish analyst$217.00
Mean target$277.50
High · most bullish analyst$316.00
Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$217.0020%

Demand moderates from the exceptional first-half orders pace, integration costs or execution issues constrain margins, and debt-funded Indicor integration causes adjusted EPS or sales contribution to fall below management's announced thresholds.

Base CaseCentral scenario
$277.5055%
Matches the consensus mean

AMETEK delivers approximately 10% full-year sales growth and adjusted EPS within the $8.20-$8.30 guidance range, while Indicor contributes approximately $350 million of 2026 sales and is modestly accretive.

Bull CaseUpside scenario
$316.0025%

Orders and sales remain broadly strong, core margin expansion persists, and Indicor integrates faster than expected while delivering at least its announced 2026 contribution and accretion. Under this outcome, AMETEK exceeds the upper end of its raised FY2026 adjusted-EPS guidance.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • Second-quarter 2026 sales reached $2.04 billion, up 15%, while adjusted diluted EPS reached $2.09, up 17%.
  • Adjusted operating income rose 18% to $544.4 million, adjusted margin expanded to 26.6%, and operating cash flow rose 35% to $483.7 million.
  • Indicor adds mission-critical instrumentation businesses with recurring consumables, service, and aftermarket revenue; AMETEK expects approximately $350 million of 2026 sales contribution and modest adjusted-EPS accretion.
Sign in / Sign up to read more
Key Investment Risks
  • The $5.0 billion all-cash Indicor transaction was planned to be funded through AMETEK's credit facility and new debt issuance, increasing financing and deleveraging sensitivity.
  • Indicor's integration spans both EIG and EMG, creating execution risk around operational integration, margin realization, and retention of expected recurring revenue.
  • AMETEK identifies tariffs, trade disputes, currency conditions, supply-chain disruption, raw-material availability, competition, regulation, and general economic conditions as factors that could cause results to differ from expectations.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.